Eckert & Ziegler: Further Increase in Earnings in the First Half of 2025

EQS-News: Eckert & Ziegler SE / Key word(s): Half Year Results/Half Year Report
Eckert & Ziegler: Further Increase in Earnings in the First Half of 2025
08.08.2025 / 07:45 CET/CEST
The issuer is solely responsible for the content of this announcement.

2nd Quarter 2025:

• Sales: € 80.6 Mio. million (PY: € 77.8 million)
• EBIT before special items: € 19.2 million (PY: € 17.5 million)
• Net income: € 11,7 million (PY: € 9.5 million)

1st Half Year 2025:

• Sales: € 148.8 million (PY: € 145.4 million)
• EBIT before special items: € 35.4 million (PY: € 32.5 million)
• Net income: € 21.4 million (PY: € 18.0 million)

Forecast 2025:

• Sales of around € 320 million (confirmed)
• EBIT before special items of around € 78 million (confirmed)

Berlin, 8 August 2025. Eckert & Ziegler SE (ISIN DE0005659700, TecDAX) slightly increased its sales in the first half of 2025 by 2% to €148.8 million compared to the same period last year. The Group's adjusted EBIT rose by 9% to €35.4 million. Net profit (from continuing and discontinued operations) increased by 19% to €21.4 million or €1.03 per share.

Sales in the Medical segment were up on the previous year at €80.5 million in the first half of the year (€69.7 million). Business with pharmaceutical radioisotopes remains the most important source of revenue. The Isotope Products segment generated external sales of €68.3 million, down €7.4 million or approximately 10% compared with the first half of 2024. Compared with the same period last year, there were both seasonal shifts and changes in the composition of the product groups.

For the current fiscal year 2025, the Executive Board confirms its profit forecast published on March 27, 2025, with sales of around €320 million and an adjusted EBIT of around €78 million.

The complete quarterly report can be viewed here: https://www.ezag.com/Q22025en

About Eckert & Ziegler.
Eckert & Ziegler SE with more than 1.000 employees is a leading specialist for isotope-related components in nuclear medicine and radiation therapy. The company offers a broad range of services and products for the radiopharmaceutical industry, from early development work to contract manufacturing and distribution. Eckert & Ziegler shares (ISIN DE0005659700) are listed in the TecDAX index of Deutsche Börse.
Contributing to saving lives.

Your contact:
Eckert & Ziegler SE, Karolin Riehle, Investor Relations
Robert-Rössle-Str. 10, 13125 Berlin, Germany
Tel.: +49 (0) 30 / 94 10 84-138, karolin.riehle@ezag.de, www.ezag.com 

08.08.2025 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com